PT3860582T - Compostos para uso no tratamento ou profilaxia de dor, inflamação e/ou autoimunidade - Google Patents
Compostos para uso no tratamento ou profilaxia de dor, inflamação e/ou autoimunidadeInfo
- Publication number
- PT3860582T PT3860582T PT207031527T PT20703152T PT3860582T PT 3860582 T PT3860582 T PT 3860582T PT 207031527 T PT207031527 T PT 207031527T PT 20703152 T PT20703152 T PT 20703152T PT 3860582 T PT3860582 T PT 3860582T
- Authority
- PT
- Portugal
- Prior art keywords
- autoimmunity
- prophylaxis
- inflammation
- pain
- compounds
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000005784 autoimmunity Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19153315 | 2019-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3860582T true PT3860582T (pt) | 2022-07-08 |
Family
ID=65228356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207031527T PT3860582T (pt) | 2019-01-23 | 2020-01-22 | Compostos para uso no tratamento ou profilaxia de dor, inflamação e/ou autoimunidade |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11891350B2 (enExample) |
| EP (1) | EP3860582B1 (enExample) |
| JP (2) | JP7611148B2 (enExample) |
| KR (1) | KR20210119403A (enExample) |
| CN (1) | CN113329746B (enExample) |
| AU (1) | AU2020210831B2 (enExample) |
| BR (1) | BR112021019476A2 (enExample) |
| CA (1) | CA3118996A1 (enExample) |
| DK (1) | DK3860582T3 (enExample) |
| ES (1) | ES2913977T3 (enExample) |
| IL (1) | IL282718B2 (enExample) |
| PL (1) | PL3860582T3 (enExample) |
| PT (1) | PT3860582T (enExample) |
| RS (1) | RS63270B1 (enExample) |
| SG (1) | SG11202111773QA (enExample) |
| WO (1) | WO2020152226A1 (enExample) |
| ZA (1) | ZA202107346B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
| WO2026037478A1 (en) | 2023-08-11 | 2026-02-19 | Novaremed AG | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642290B2 (en) | 2002-10-03 | 2010-01-05 | Novaremed Limited | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| US7674829B2 (en) | 2004-03-26 | 2010-03-09 | Novaremed Limited | Compounds for the treatment of AIDS and other viral diseases |
| GB0804213D0 (en) | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| WO2011030205A1 (en) | 2009-09-09 | 2011-03-17 | Novaremed Ltd. | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation |
| US8802734B2 (en) | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| GB0916073D0 (en) | 2009-09-14 | 2009-10-28 | Cintec Int Ltd | Improvements in and relating to building anchor systems |
| CN103998420B (zh) * | 2011-12-08 | 2018-04-17 | 诺瓦麦有限公司 | (s)2‑n(3‑o‑(丙‑2‑醇)‑1‑丙基‑4‑羟基苯)‑3‑苯基丙酰胺的分离的立体异构形式 |
-
2020
- 2020-01-22 RS RS20220510A patent/RS63270B1/sr unknown
- 2020-01-22 KR KR1020217023524A patent/KR20210119403A/ko not_active Ceased
- 2020-01-22 BR BR112021019476A patent/BR112021019476A2/pt unknown
- 2020-01-22 PT PT207031527T patent/PT3860582T/pt unknown
- 2020-01-22 SG SG11202111773QA patent/SG11202111773QA/en unknown
- 2020-01-22 US US17/295,788 patent/US11891350B2/en active Active
- 2020-01-22 AU AU2020210831A patent/AU2020210831B2/en active Active
- 2020-01-22 CA CA3118996A patent/CA3118996A1/en active Pending
- 2020-01-22 DK DK20703152.7T patent/DK3860582T3/da active
- 2020-01-22 JP JP2021543276A patent/JP7611148B2/ja active Active
- 2020-01-22 ES ES20703152T patent/ES2913977T3/es active Active
- 2020-01-22 EP EP20703152.7A patent/EP3860582B1/en active Active
- 2020-01-22 CN CN202080010393.8A patent/CN113329746B/zh active Active
- 2020-01-22 IL IL282718A patent/IL282718B2/en unknown
- 2020-01-22 PL PL20703152.7T patent/PL3860582T3/pl unknown
- 2020-01-22 WO PCT/EP2020/051528 patent/WO2020152226A1/en not_active Ceased
-
2021
- 2021-09-23 ZA ZA2021/07346A patent/ZA202107346B/en unknown
-
2024
- 2024-12-23 JP JP2024226332A patent/JP2025036479A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2913977T3 (es) | 2022-06-07 |
| KR20210119403A (ko) | 2021-10-05 |
| SG11202111773QA (en) | 2021-11-29 |
| US20220002228A1 (en) | 2022-01-06 |
| CA3118996A1 (en) | 2020-07-30 |
| US11891350B2 (en) | 2024-02-06 |
| JP7611148B2 (ja) | 2025-01-09 |
| JP2025036479A (ja) | 2025-03-14 |
| RS63270B1 (sr) | 2022-06-30 |
| EP3860582A1 (en) | 2021-08-11 |
| IL282718A (en) | 2021-06-30 |
| PL3860582T3 (pl) | 2022-08-01 |
| JP2022518288A (ja) | 2022-03-14 |
| ZA202107346B (en) | 2023-10-25 |
| AU2020210831B2 (en) | 2025-02-13 |
| BR112021019476A2 (pt) | 2021-11-30 |
| EP3860582B1 (en) | 2022-05-04 |
| CN113329746A (zh) | 2021-08-31 |
| IL282718B1 (en) | 2024-04-01 |
| WO2020152226A1 (en) | 2020-07-30 |
| IL282718B2 (en) | 2024-08-01 |
| CN113329746B (zh) | 2025-05-02 |
| AU2020210831A1 (en) | 2021-05-20 |
| DK3860582T3 (da) | 2022-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202103977B (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| IL289758B2 (en) | Proportin inhibitors for use in the prevention and treatment of kidney injury | |
| ZA202207493B (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| IL275132A (en) | C5AR inhibitors for use in the treatment of iatrogenic pain caused by chemotherapy | |
| IL282718A (en) | Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
| GB201918413D0 (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| GB201918414D0 (en) | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency | |
| IL284298A (en) | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases | |
| EP4017496A4 (en) | FORMULATIONS FOR THE PREVENTION AND/OR TREATMENT OF PERIPHERAL NEUROPATHY AND ITS ASSOCIATED DISEASES | |
| EP3782627A4 (en) | MEDICINAL PRODUCT USED TO PREVENT AND / OR TREAT PAIN AND / OR FEVER, A COMBINATION PRODUCT, AND USE OF THEM | |
| PL3713590T3 (pl) | Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi | |
| PL4346847T3 (pl) | Kompleks wielojonowy do stosowania w profilaktyce lub leczeniu zapalenia neurogennego | |
| IL276228A (en) | Compounds and preparations for the treatment of pain | |
| GB201918416D0 (en) | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency | |
| GB2610895B (en) | Composition for use in the treatment and/or prevention of mycotoxic disease | |
| GB2574944B (en) | Methods and compositions for the treatment of pain and/or inflammation | |
| GB201918539D0 (en) | Compounds for use in treatment and prophylaxis | |
| AU2019900258A0 (en) | Pyran compounds and their use in the treatment of pain | |
| PL3813843T3 (pl) | Kompozycja do stosowania w zapobieganiu i/lub leczeniu chorób układu kostno-stawowego | |
| HK40074743A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| HK40076794A (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| GB202107297D0 (en) | Composition for use in the treatment and/or prevention of mycotoxic disease |